Newcelx LTD. (NCEL) SEC Filings — 2025
43 SEC filings for Newcelx LTD. (NCEL) in 2025.
Filings
- Newcelx LTD. 6-K Filing — 6-K · Dec 11, 2025
- Newcelx LTD. 6-K Filing — 6-K · Nov 20, 2025
- NewcelX Ltd. Adds Top Neurologist to Scientific Advisory Board — 6-K · Nov 17, 2025
- Newcelx LTD. 6-K Filing — 6-K · Nov 7, 2025
- NewcelX Ltd. CEO Issues Letter to Shareholders — 6-K · Nov 4, 2025
- Newcelx LTD. 6-K Filing — 6-K · Nov 3, 2025
- NLS Pharma Expands CNS Pipeline with Aexon Labs' AEX-6xx Series — 6-K · Oct 30, 2025
- NLS Pharmaceutics Merges Subsidiary with Kadimastem — 6-K · Oct 29, 2025
- NLS Pharmaceutics & Kadimastem Merger Conditions Met — 6-K · Oct 28, 2025
- NLS Pharmaceutics Partners for Gene-Edited Cell Therapies — 6-K · Oct 27, 2025
- NLS Pharmaceutics & Kadimastem Merger Gets Nasdaq Nod — 6-K · Oct 23, 2025
- NLS Pharmaceutics Ltd. Merges with Kadimastem Ltd. — 6-K · Oct 10, 2025
- NLS Pharmaceutics Files Interim Financials — 6-K · Oct 6, 2025
- NLS Pharmaceutics Shareholders Approve Merger with Kadimastem — 6-K · Sep 30, 2025
- NLS Pharmaceutics Auditor Resigns Amidst Business Acquisition — 6-K · Sep 19, 2025
- NLS Pharmaceutics Merger Registration Statement Effective — 6-K · Sep 10, 2025
- NLS Pharmaceutics Secures Hong Kong Patent for Diabetes Tech — 6-K · Sep 4, 2025
- NLS Pharmaceutics Amends Merger Agreement for Seventh Time — 6-K · Aug 29, 2025
- NLS Pharmaceutics Reschedules Shareholder Meeting for Kadimastem Deal — 6-K · Aug 25, 2025
- NLS Pharmaceutics Exchanges Warrants with Alpha Capital — 6-K · Aug 6, 2025
- NLS Pharmaceutics Amends Merger Agreement for Sixth Time — 6-K · Jul 18, 2025
- NLS Pharma diabetes therapy gets BIRD Foundation milestone payment — 6-K · Jul 17, 2025
- NLS Pharmaceutics Amends Merger Agreement Again — 6-K · Jul 1, 2025
- NLS Pharmaceutics Amends Private Placement Agreement — 6-K · Jun 30, 2025
- NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Jun 16, 2025
- NLS Pharmaceutics Schedules June 30th Annual Shareholder Meeting — 6-K · Jun 10, 2025
- NLS Pharmaceutics Amends Merger Agreement for Fourth Time — 6-K · Jun 6, 2025
- NLS Pharmaceutics Files 2024 Annual Report — 20-F · May 16, 2025
- NLS Pharmaceutics Amends Merger Agreement with Kadimastem — 6-K · May 5, 2025
- NLS Pharmaceutics Director Resigns — 6-K · Apr 24, 2025
- NLS Pharmaceutics: Mazindol Shows Promise Against Fentanyl Reward — 6-K · Apr 15, 2025
- NLS Pharmaceutics Raises $3M in Private Placement — 6-K · Mar 31, 2025
- NLS Pharmaceutics CEO Letter to Shareholders Filed — 6-K · Mar 10, 2025
- NLS Pharmaceutics: AEX-2 Preclinical Data Shows Promise — 6-K · Feb 27, 2025
- NLS Pharmaceutics Subs Complete FDA Pre-IND Meeting for Diabetes Drug — 6-K · Feb 25, 2025
- NLS Pharma & Kadimastem Target Diabetes Beyond GLP-1 — 6-K · Feb 10, 2025
- NLS Pharmaceutics and Kadimastem Merger Approved — 6-K · Jan 31, 2025
- NLS Pharmaceutics Submits Abstracts to ASCP Meeting — 6-K · Jan 30, 2025
- NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence — 6-K · Jan 28, 2025
- NLS Pharmaceutics Merger Vote Scheduled — 6-K · Jan 16, 2025
- NLS Pharmaceutics Shareholders Approve All Agenda Items — 6-K · Jan 14, 2025
- NLS Pharmaceutics Closes $500K Fundraising at Premium — 6-K · Jan 8, 2025
- NLS Pharmaceutics Shareholders Approve Most Proposals — 6-K · Jan 7, 2025